Abstract | BACKGROUND: METHODS: This study was a retrospective chart review of the efficacy of aripiprazole augmentation in 30 treatment-resistant unipolar depression patients who had failed multiple previous antidepressant trials and had also failed augmentation with at least one other atypical neuroleptic. Prospective Global Assessment of Functioning and Clinical Global Impressions-Improvement scores were completed on each patient throughout treatment. RESULTS: Utilizing an intent-to-treat analysis (including 9 patients who dropped out prior to completion of 6 weeks), 46.7% (14/30) patients were rated much improved or very much improved with treatment. This improvement negatively correlated with Thase-Rush staging of treatment resistance. GAF scores also showed a significant improvement. Six of the 14 patients who initially improved subsequently relapsed (yielding a long-term net response rate of 26.7%). CONCLUSION:
|
Authors | James G Barbee, Erich J Conrad, Nowal J Jamhour |
Journal | Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists
(Ann Clin Psychiatry)
2004 Oct-Dec
Vol. 16
Issue 4
Pg. 189-94
ISSN: 1040-1237 [Print] United States |
PMID | 15702566
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Antipsychotic Agents
- Piperazines
- Quinolones
- Aripiprazole
|
Topics |
- Adult
- Aged
- Antipsychotic Agents
(therapeutic use)
- Aripiprazole
- Depressive Disorder
(drug therapy, psychology)
- Drug Resistance
- Female
- Humans
- Male
- Middle Aged
- Piperazines
(therapeutic use)
- Psychiatric Status Rating Scales
- Quinolones
(therapeutic use)
- Retrospective Studies
- Treatment Outcome
|